Surveillance Frequency for Barrett's Esophagus

Surveillance Recommendations Based on Barrett's Segment Length

For patients with short segment Barrett's (<3 cm) with intestinal metaplasia, the American Gastroenterological Association recommends surveillance endoscopy every 3-5 years 1, 2, 3
For patients with long segment Barrett's (≥3 cm), the British Society of Gastroenterology recommends surveillance endoscopy every 2-3 years 3, 4

The American College of Gastroenterology recommends using high-definition white light endoscopy and documenting the extent of Barrett's using the Prague classification (circumferential and maximal extent) 1, 2
The American Society for Gastrointestinal Endoscopy recommends obtaining 4-quadrant biopsies every 2 cm of the Barrett's segment and taking targeted biopsies of any visible lesions or abnormalities 2, 4, 5

For patients with no dysplasia, the American Gastroenterological Association recommends continuing surveillance every 3-5 years for short segments (<3 cm) or every 2-3 years for long segments (≥3 cm) 2, 3, 4
For patients with low-grade dysplasia, the American College of Gastroenterology recommends confirming with expert pathologist review and repeating endoscopy in 6-12 months 5, 6
For patients with high-grade dysplasia, the American Society for Gastrointestinal Endoscopy recommends repeating endoscopy in 3 months if no endoscopic eradication therapy is performed 5

The American College of Gastroenterology recommends that patients be on at least daily proton pump inhibitor therapy 2
The American Society for Gastrointestinal Endoscopy recommends considering endoscopic eradication therapy for patients with confirmed dysplasia 6
After successful endoscopic eradication therapy, the American College of Gastroenterology recommends more frequent surveillance: for high-grade dysplasia/cancer baseline, follow-up at 3, 6, and 12 months and annually thereafter; for low-grade dysplasia baseline, follow-up at 1 and 3 years 6

The British Society of Gastroenterology recommends avoiding inadequate biopsy sampling, which results in significantly lower rates of dysplasia detection, by adhering to the Seattle protocol (4-quadrant biopsies every 2 cm) 3
The American Gastroenterological Association recommends confirming all cases of suspected dysplasia by a second GI pathologist due to significant interobserver variability 2, 4

For indefinite for dysplasia, consider endoscopic surveillance at 6-month intervals with optimization of acid-suppressant medication 7
The American Gastroenterological Association recommends using high-resolution white light endoscopy for all surveillance procedures, obtaining 4-quadrant biopsies every 2 cm of Barrett's segment for patients without known dysplasia, and obtaining 4-quadrant biopsies every 1 cm for patients with known or suspected dysplasia 8, 7
Adherence to recommended biopsy protocols is associated with higher rates of dysplasia and cancer detection, and endoscopic surveillance can reduce mortality from esophageal adenocarcinoma through early detection of treatable cancers 8

After endoscopic submucosal dissection (ESD) for T1a esophageal adenocarcinoma (EAC), the first EGD should be performed at 6 months, then every 6 months for a total of 2 years, then annually, according to the American Gastroenterological Association 9
After ESD for T1b EAC (<500 μm submucosal invasion), the first EGD should be performed at 3 months, the second at 6 months, then every 6 months for a total of 2 years 9

Short‑segment Barrett’s (< 3 cm) – Perform surveillance endoscopy every 3–5 years. The American Gastroenterological Association recommends this interval based on the low annual cancer risk in this population. 10
Long‑segment Barrett’s (≥ 3 cm) – Perform surveillance endoscopy every 2–3 years. The British Society of Gastroenterology endorses this schedule, reflecting the higher malignancy risk with longer segments. 11

Seattle protocol – Obtain four‑quadrant biopsies every 2 cm throughout the Barrett’s segment to maximize dysplasia detection. 10
Targeted sampling – First take directed biopsies of any visible mucosal irregularities or lesions before performing random biopsies. 10
Imaging standard – Use high‑definition white‑light endoscopy as the standard imaging modality for surveillance examinations. 10
Impact of adherence – Centers that consistently follow the Seattle protocol demonstrate significantly higher rates of dysplasia and cancer detection compared with those that do not. 10
Pathology confirmation – Any diagnosis of dysplasia should be reviewed by a second expert gastrointestinal pathologist before altering surveillance intervals, because low‑grade dysplasia is frequently over‑called in community practice. 10
Adherence gaps – Studies show suboptimal adherence to the Seattle protocol, especially in patients with extensive Barrett’s metaplasia, who are at the highest risk for progression. 10

Fitness for definitive therapy – Surveillance is appropriate only for patients who are medically fit to undergo endoscopic therapy or esophagectomy should high‑grade dysplasia or cancer be identified. 11

Avoid biopsies in severe erosive esophagitis (Los Angeles grade C or D). Optimize acid‑suppression therapy first, then repeat endoscopy after inflammation has resolved before obtaining biopsies. This recommendation is supported by two separate Gastroenterology publications from 2016. [12][13]